clinical trial · NCT07292441
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
Overweight or ObesityGZR18 injectionPlacebo
brief summary
This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on body weight. In this study, it is planned to include subjects who have participated in the original study and completed the study contents of the original protocol. All subjects will maintain a regular diet and exercise lifestyle during the study.
started
Jan 22, 2026
primary completion
Sep 1, 2027
completion
Oct 1, 2027
last updated
Mar 11, 2026
official title
A Multicenter Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol